Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Cash from Operations (2023 - 2025)

NewAmsterdam Pharma's Cash from Operations history spans 3 years, with the latest figure at 40875000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 9.06% year-over-year to 40875000.0; the TTM value through Dec 2025 reached 147783000.0, up 6.8%, while the annual FY2025 figure was 147783000.0, 6.8% up from the prior year.
  • Cash from Operations for Q4 2025 was 40875000.0 at NewAmsterdam Pharma, down from 32769000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 12502000.0 in Q3 2024 and bottomed at 54602000.0 in Q1 2024.
  • The 3-year median for Cash from Operations is 36974500.0 (2024), against an average of 37297083.33.
  • The largest annual shift saw Cash from Operations surged 73.39% in 2024 before it plummeted 162.11% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 33074000.0 in 2023, then fell by 13.32% to 37481000.0 in 2024, then dropped by 9.06% to 40875000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Cash from Operations are 40875000.0 (Q4 2025), 32769000.0 (Q3 2025), and 37671000.0 (Q2 2025).